A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients L1215.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Procaine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Procaine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Procaine. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Procaine. |
| Magnesium sulfate | The therapeutic efficacy of Procaine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Procaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Procaine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Procaine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Procaine. |
| Orphenadrine | Procaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Procaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Procaine. |
| Pramipexole | Procaine may increase the sedative activities of Pramipexole. |
| Ropinirole | Procaine may increase the sedative activities of Ropinirole. |
| Rotigotine | Procaine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Procaine. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Procaine is combined with Sodium oxybate. |
| Suvorexant | Procaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Thalidomide | Procaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Procaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Prilocaine. |
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Memantine | The risk or severity of adverse effects can be increased when Procaine is combined with Memantine. |
| Dipyridamole | The therapeutic efficacy of Procaine can be decreased when used in combination with Dipyridamole. |
| Irinotecan | The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Procaine. |
| Ephedrine | Procaine may increase the neuromuscular blocking activities of Ephedrine. |
| Sar9, Met (O2)11-Substance P | Procaine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P. |
| Mirabegron | Procaine may increase the neuromuscular blocking activities of Mirabegron. |
| Moxisylyte | Procaine may increase the neuromuscular blocking activities of Moxisylyte. |
| Propacetamol | Procaine may increase the neuromuscular blocking activities of Propacetamol. |
| Pegvisomant | Pegvisomant may increase the neuromuscular blocking activities of Procaine. |
| Mefloquine | The risk or severity of methemoglobinemia can be increased when Mefloquine is combined with Procaine. |
| Tacrine | Tacrine may increase the neuromuscular blocking activities of Procaine. |
| Sulpiride | Sulpiride may increase the neuromuscular blocking activities of Procaine. |
| Profenamine | Profenamine may increase the neuromuscular blocking activities of Procaine. |
| Gallamine triethiodide | Gallamine triethiodide may increase the neuromuscular blocking activities of Procaine. |
| Cisplatin | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Procaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Procaine. |
| Pyridostigmine | Pyridostigmine may increase the neuromuscular blocking activities of Procaine. |
| Nizatidine | Nizatidine may increase the neuromuscular blocking activities of Procaine. |
| Galantamine | Galantamine may increase the neuromuscular blocking activities of Procaine. |
| Isoflurophate | Isoflurophate may increase the neuromuscular blocking activities of Procaine. |
| Diethylcarbamazine | Diethylcarbamazine may increase the neuromuscular blocking activities of Procaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Cocaine. |
| Hexafluronium | Hexafluronium may increase the neuromuscular blocking activities of Procaine. |
| Trimethaphan | Procaine may increase the neuromuscular blocking activities of Trimethaphan. |
| Doxacurium | Procaine may increase the neuromuscular blocking activities of Doxacurium. |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Procaine is combined with Chloroprocaine. |
| Tubocurarine | Procaine may increase the neuromuscular blocking activities of Tubocurarine. |
| Pancuronium | Pancuronium may increase the neuromuscular blocking activities of Procaine. |
| Pipecuronium | Pipecuronium may increase the neuromuscular blocking activities of Procaine. |
| Aclidinium | Procaine may increase the neuromuscular blocking activities of Aclidinium. |
| Terbutaline | Terbutaline may increase the neuromuscular blocking activities of Procaine. |
| Mechlorethamine | The risk or severity of methemoglobinemia can be increased when Mechlorethamine is combined with Procaine. |
| Demecarium | Demecarium may increase the neuromuscular blocking activities of Procaine. |
| Physostigmine | Physostigmine may increase the neuromuscular blocking activities of Procaine. |
| Rivastigmine | Rivastigmine may increase the neuromuscular blocking activities of Procaine. |
| Edrophonium | Edrophonium may increase the neuromuscular blocking activities of Procaine. |
| Procainamide | Procainamide may increase the neuromuscular blocking activities of Procaine. |
| Ambenonium | Ambenonium may increase the neuromuscular blocking activities of Procaine. |
| Ketamine | Ketamine may increase the neuromuscular blocking activities of Procaine. |
| Decamethonium | Decamethonium may increase the neuromuscular blocking activities of Procaine. |
| Ginkgo biloba | Ginkgo biloba may increase the neuromuscular blocking activities of Procaine. |
| Neostigmine | Neostigmine may increase the neuromuscular blocking activities of Procaine. |
| Bambuterol | Procaine may increase the neuromuscular blocking activities of Bambuterol. |
| 1,10-Phenanthroline | 1,10-Phenanthroline may increase the neuromuscular blocking activities of Procaine. |
| Thiotepa | The risk or severity of methemoglobinemia can be increased when Thiotepa is combined with Procaine. |
| Huperzine A | Huperzine A may increase the neuromuscular blocking activities of Procaine. |
| Phenserine | Phenserine may increase the neuromuscular blocking activities of Procaine. |
| Regramostim | Regramostim may increase the neuromuscular blocking activities of Procaine. |
| Aprotinin | Aprotinin may increase the neuromuscular blocking activities of Procaine. |
| Betaine | Betaine may increase the neuromuscular blocking activities of Procaine. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Capsaicin. |
| Coumaphos | Coumaphos may increase the neuromuscular blocking activities of Procaine. |
| Dichlorvos | Dichlorvos may increase the neuromuscular blocking activities of Procaine. |
| Fenthion | Fenthion may increase the neuromuscular blocking activities of Procaine. |
| Metrifonate | Metrifonate may increase the neuromuscular blocking activities of Procaine. |
| Acotiamide | Acotiamide may increase the neuromuscular blocking activities of Procaine. |
| Methanesulfonyl Fluoride | Methanesulfonyl Fluoride may increase the neuromuscular blocking activities of Procaine. |
| Paraoxon | Paraoxon may increase the neuromuscular blocking activities of Procaine. |
| Tyrothricin | The risk or severity of methemoglobinemia can be increased when Tyrothricin is combined with Procaine. |
| Ipidacrine | Ipidacrine may increase the neuromuscular blocking activities of Procaine. |
| Distigmine | Distigmine may increase the neuromuscular blocking activities of Procaine. |
| Tretamine | The risk or severity of methemoglobinemia can be increased when Tretamine is combined with Procaine. |
| Posiphen | Posiphen may increase the neuromuscular blocking activities of Procaine. |
| Butyrylthiocholine | Procaine may increase the neuromuscular blocking activities of Butyrylthiocholine. |
| Methylphosphinic Acid | Methylphosphinic Acid may increase the neuromuscular blocking activities of Procaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Oxybuprocaine. |
| Benzonatate | Procaine may increase the neuromuscular blocking activities of Benzonatate. |
| Apraclonidine | Procaine may increase the alpha-adrenergic activities of Apraclonidine. |
| Atomoxetine | The risk or severity of adverse effects can be increased when Procaine is combined with Atomoxetine. |
| Betahistine | The metabolism of Betahistine can be decreased when combined with Procaine. |
| Bezafibrate | Procaine may increase the hepatotoxic activities of Bezafibrate. |
| Buprenorphine | Procaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Bupropion | The risk or severity of adverse effects can be increased when Procaine is combined with Bupropion. |
| Buspirone | The risk or severity of hypertension can be increased when Procaine is combined with Buspirone. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Procaine. |